Latest episode
1. Lighting the touch paper for next generation nucleic acid therapies
32:06||Season 2, Ep. 1In this episode Mike Ward, Clarivate’s Head of Thought Leadership for Life sciences and healthcare, spoke to Johnny Ohlson, Founder of Touchlight, a company who has developed a novel synthetic DNA vector. In recent years, we've seen that by harnessing the power of DNA, it has been possible to achieve success in treating previously incurable hereditary diseases and even tackle major pandemics. However, whether the answer is cell or gene therapies or RNA vaccines, one thing they all have in common is that they require DNA in some form or another as the starting material. Through Touchlight, Johnny Ohlson and his talented team have built a business that can make DNA at unprecedented speed, scale and purity. Johnny, a serial entrepreneur not originally from a biopharma background, shares with us his story of breaking successfully into a complex industry. This podcast demonstrates that innovation at its heart is more about a combination of vision, relationships and talented people rather than prior experience.
More episodes
View all episodes
46. Realizing the patient-friendly future of clinical trials
23:02||Season 1, Ep. 46In this episode of Conversations in Healthcare, Ergomed founder Dr. Miroslav Reljanović talks to Mike Ward about how the COVID-19 pandemic has nudged clinical trials towards greater efficiency and inclusivity – and what’s needed to make good on this promising trend.
45. How Patient Connect addresses unmet needs at the point of care
22:32||Season 1, Ep. 45In this episode of Conversations in Healthcare, Mike Ward speaks with Dr. Grace Lomax, Clinical Director at Patient Connect, a part of Clarivate. Grace’s experience as a physician highlighted numerous unmet needs beyond just clinical issues – especially around healthcare literacy, education at the point of care, adherence and more. She discusses how Patient Connect uses technology and communication strategies to inform and support patients at the point of care, and shares examples of campaigns that improved outcomes in cancer, hypertension, rare disease and asthma.
44. Social determinants: barriers to healthcare impacting racial and ethnic minorities
45:59||Season 1, Ep. 44In this episode of Conversations in Healthcare, Matthew Arnold, Principal Analyst at Clarivate speaks with Dr. Kenton Johnston, Associate Professor of Health Management and Policy at Saint Louis University about disparities in the US health system. Matthew and Ken discuss both the historical context as well as the evolution of the system since the establishment of the Affordable Care Act, and how the entire spectrum of the healthcare system can work to address social determinants of health. Learn more in the full episode.
43. How Novo Ventures prioritized their investment strategy during the pandemic
25:50||Season 1, Ep. 43In this episode of Conversations in Healthcare, Mike Ward speaks with Naveed Saddiqi, Senior Partner at Novo Ventures, one of the largest venture capital groups in the life sciences sector. Naveed shares about the firm’s mandate to generate funds for the Novo Nordisk Foundation, how the pandemic impacted their investment strategy and what excites him most in the life sciences industry. Learn more in the full episode, which was recorded in collaboration with One Nucleus's ON Helix conference (June 2021).
42. How Healx uses AI to transform rare disease drug discovery
27:52||Season 1, Ep. 42In this episode of Conversations in Healthcare, Mike Ward speaks with Dr. Tim Guilliams, the co-founder and CEO of Healx. Healx is an artificial intelligence-powered technology company that's dedicated to helping rare disease patients access life improving treatments. Mike and Tim discuss the company’s innovative approach to drug discovery, choosing which rare diseases to target and how patients are shaping their priorities. Learn more in the full episode, which was recorded in collaboration with One Nucleus's ON Helix conference (June 2021).
41. How the pandemic shifted Roche’s priorities and R&D investments
31:20||Season 1, Ep. 41In this episode of Conversations in Healthcare, Mike Ward speaks with Richard Erwin, general manager and managing director of Roche Products Limited (UK), which was recorded in collaboration with One Nucleus's ON Helix conference (June 2021). Richard shares how the pandemic has shifted Roche’s priorities and why the organization has heavily increased their investment in R&D. Learn more in the full episode.